We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Novel Dataset of Plasma Cells to Aid Diagnosis of Multiple Myeloma

By LabMedica International staff writers
Posted on 06 Feb 2025
Print article
Image: The plasma cell dataset was created to assist in the accurate diagnosis (Photo courtesy of Shutterstock)
Image: The plasma cell dataset was created to assist in the accurate diagnosis (Photo courtesy of Shutterstock)

Myeloma is a rare blood cancer that originates in plasma cells, a type of immune cell responsible for producing antibodies that help fight infections. The disease begins when an abnormal plasma cell starts to uncontrollably divide in the bone marrow — the soft tissue found inside bones — leading to the production of large numbers of genetically identical, abnormal cells. These cells, known as clonal cells, do not function as normal plasma cells would. Instead, they crowd out healthy blood cells in the bone marrow, disrupting their growth. When myeloma affects more than one bone marrow site, which is typically the case, it is referred to as multiple myeloma (MM). To confirm a diagnosis of myeloma, doctors perform a biopsy, which involves collecting a sample of bone marrow cells. If myeloma is present, at least 10% of the cells in the sample will be abnormal plasma cells. This sample is usually analyzed manually by an expert, who examines the tissue under a microscope and counts the cells. However, this process is time-consuming and labor-intensive, requiring significant resources. Additionally, inconsistencies in the interpretation of results can occur, affecting the diagnostic accuracy, depending on the evaluator’s expertise. This can be particularly challenging in regions with fewer trained professionals.

To address these issues and enhance the myeloma diagnostic process, researchers from the Federal University of Bahia Institute of Computing (Salvador, Brazil) have developed a large dataset of bone marrow cells from patients with MM and other blood disorders. This dataset, named PCMMD (Plasma Cells for Multiple Myeloma Diagnosis), was created to assist in the accurate diagnosis of MM. The data was collected from individuals diagnosed and treated within the Brazilian Public Health System. Thousands of bone marrow cells from these patients were photographed using a smartphone camera after being visualized under a microscope. Hematologists, experts in blood disorders, then manually analyzed the images, labeling the cells as either plasma or non-plasma cells. The researchers believe that this dataset could improve the efficiency and accuracy of diagnosing MM, especially in resource-limited areas where trained experts are scarce.

In addition to helping doctors with less experience identify myeloma cells, the researchers hope their dataset will serve as a foundation for developing AI-based systems that can automatically distinguish plasma cells from non-plasma cells. Such advancements, they noted, could enhance the diagnostic process for all clinicians and ultimately benefit patients. To test the potential of their dataset, the researchers used it to train an AI-based algorithm to recognize plasma and non-plasma cells in bone marrow samples. The results, published in Scientific Data, showed that the model performed well, correctly classifying cells. The disease status predicted by the AI model matched the diagnosis made by an expert for nine out of ten patients. Given the simple, smartphone-based methodology, the scientists highlighted that this approach could be easily implemented even in resource-constrained environments. The team aims for their dataset to be widely available, encouraging other researchers to build upon it and develop even more advanced AI models to improve myeloma diagnosis.

“Considering all analyses … we are confident that our dataset contains valuable patterns to identify plasma and non-plasma cells, providing an important and low-cost setup to support hematologists,” the researchers wrote. “The availability of our dataset and benchmark model support ongoing research and development in the field, promoting continuous improvement in the accuracy and efficiency of MM diagnostics.”

Related Links:
Federal University of Bahia Institute of Computing 

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TRAb Immunoassay
Chorus TRAb
New
Blood Gas and Chemistry Analysis System
Edan i500

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.